| Literature DB >> 6231103 |
F M Muggia, A A Tsiatis, M J O'Connell, J H Glick, R W Opfell, A Coren.
Abstract
A phase II trial of PALA in malignant lymphoma was carried out by the Eastern Cooperative Oncology Group. The occurrence of hematologic toxicity in 17 of 35 patients in the study was noteworthy and was possibly related to prior therapy and/or marrow involvement. The finding of thromboembolic phenomena in four of five autopsied patients was also noteworthy. No antitumor activity was recorded. This experience discourages further trials of PALA in patients with malignant lymphoma.Entities:
Mesh：
Substances：
Year: 1984 PMID： 6231103
Source DB: PubMed Journal: Cancer Treat Rep ISSN： 0361-5960